130 related articles for article (PubMed ID: 7683894)
1. [Changes in serum levels of beta 2-microglobulin, neopterin and 2',5'-oligoadenylate synthase activity during clearance of hepatitis B virus with or without acute phase in transaminases].
Carreño García V; Hernández-Guío C; Bartolomé Nebreda J; Quiroga Estévez JA
Rev Esp Enferm Dig; 1993 Mar; 83(3):169-75. PubMed ID: 7683894
[TBL] [Abstract][Full Text] [Related]
2. Serum and urinary neopterin levels in patients with chronic active hepatitis B treated with interferon.
Daito K; Suou T; Kawasaki H
Res Commun Chem Pathol Pharmacol; 1994 Mar; 83(3):303-16. PubMed ID: 8008980
[TBL] [Abstract][Full Text] [Related]
3. 2',5'-oligoadenylate synthetase, neopterin and beta 2-microglobulin in asymptomatic HIV-infected individuals.
Witt PL; Spear GT; Lindstrom MJ; Kessler HA; Borden EC; Phair J; Landay AL
AIDS; 1991 Mar; 5(3):289-93. PubMed ID: 2059368
[TBL] [Abstract][Full Text] [Related]
4. [Changes of serum 2',5'-oligoadenylate synthetase activity and neopterin during interferon treatment for chronic hepatitis C].
Daito K; Suou T; Kawasaki H
Nihon Rinsho; 1995 Sep; 53 Suppl(Pt 1):981-5. PubMed ID: 7563914
[No Abstract] [Full Text] [Related]
5. Pilot study of natural human interleukin-2 in patients with chronic hepatitis B. Immunomodulatory and antiviral effects.
Tilg H; Vogel W; Tratkiewicz J; Aulitzky WE; Herold M; Gruber M; Geissler D; Umlauft F; Judmaier G; Schwulera U
J Hepatol; 1993 Sep; 19(2):259-67. PubMed ID: 8301059
[TBL] [Abstract][Full Text] [Related]
6. Comparative study of clinical, histological, and immunological responses to interferon therapy in type non-A, non-B, and type B chronic hepatitis.
Nakano Y; Kiyosawa K; Sodeyama T; Tanaka E
Am J Gastroenterol; 1990 Jan; 85(1):24-9. PubMed ID: 1688684
[TBL] [Abstract][Full Text] [Related]
7. Elevated levels of 2',5'-oligoadenylate synthetase activity in peripheral blood mononuclear cells and serum during acute exacerbation of chronic hepatitis B.
Shindo M; Okuno T; Arai K; Matsumoto M; Takeda M; Takino T; Sokawa Y
Hepatology; 1989 May; 9(5):715-9. PubMed ID: 2468593
[TBL] [Abstract][Full Text] [Related]
8. Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon-beta serine.
Goldstein D; Sielaff KM; Storer BE; Brown RR; Datta SP; Witt PL; Teitelbaum AP; Smalley RV; Borden EC
J Natl Cancer Inst; 1989 Jul; 81(14):1061-8. PubMed ID: 2472488
[TBL] [Abstract][Full Text] [Related]
9. Biological and clinical effects of the combination of beta- and gamma-interferons administered as a 5-day continuous infusion.
Schiller JH; Storer B; Witt PL; Nelson B; Brown RR; Horisberger M; Grossberg S; Borden EC
Cancer Res; 1990 Aug; 50(15):4588-94. PubMed ID: 2114942
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamics of recombinant IFN-beta during long-term treatment of malignant melanoma.
Fierlbeck G; Ulmer A; Schreiner T; Stroebel W; Schiebel U; Brzoska J
J Interferon Cytokine Res; 1996 Oct; 16(10):777-81. PubMed ID: 8910762
[TBL] [Abstract][Full Text] [Related]
11. Serum 2',5'-oligoadenylate synthetase activity during interferon treatment of chronic hepatitis B.
Shindo M; Okuno T; Matsumoto M; Takeda M; Takino T; Sokawa J; Iwata A; Sokawa Y
Hepatology; 1988; 8(2):366-70. PubMed ID: 2451634
[TBL] [Abstract][Full Text] [Related]
12. Serum concentrations of 2',5'-oligoadenylate synthetase, neopterin, and beta-glucan in patients with chronic fatigue syndrome and in patients with major depression.
Matsuda J; Gohchi K; Gotoh N
J Neurol Neurosurg Psychiatry; 1994 Aug; 57(8):1015-6. PubMed ID: 8057103
[No Abstract] [Full Text] [Related]
13. Phase I trial of an oral immunomodulator and interferon inducer in cancer patients.
Witt PL; Ritch PS; Reding D; McAuliffe TL; Westrick L; Grossberg SE; Borden EC
Cancer Res; 1993 Nov; 53(21):5176-80. PubMed ID: 8221654
[TBL] [Abstract][Full Text] [Related]
14. Indomethacin enhances serum 2'5'-oligoadenylate synthetase in patients with hepatitis B and C virus chronic active hepatitis.
Andreone P; Cursaro C; Gramenzi A; Buzzi A; Miniero R; Sprovieri G; Gasbarrini G
J Hepatol; 1994 Dec; 21(6):984-8. PubMed ID: 7699263
[TBL] [Abstract][Full Text] [Related]
15. [Mechanisms of the effect of interferon (IFN) therapy in patients with type B and C chronic hepatitis].
Karino Y
Hokkaido Igaku Zasshi; 1993 May; 68(3):297-309. PubMed ID: 7686526
[TBL] [Abstract][Full Text] [Related]
16. A direct comparison of biological response modulation and clinical side effects by interferon-beta ser, interferon-gamma, or the combination of interferons beta ser and gamma in humans.
Schiller JH; Storer B; Paulnock DM; Brown RR; Datta SP; Witt PL; Borden EC
J Clin Invest; 1990 Oct; 86(4):1211-21. PubMed ID: 2120284
[TBL] [Abstract][Full Text] [Related]
17. Effects of interferon on intrahepatic human leukocyte antigens and lymphocyte subsets in patients with chronic hepatitis B and C.
Hayata T; Nakano Y; Yoshizawa K; Sodeyama T; Kiyosawa K
Hepatology; 1991 Jun; 13(6):1022-8. PubMed ID: 1711000
[TBL] [Abstract][Full Text] [Related]
18. 2',5'-Oligoadenylate synthetase activity in peripheral blood lymphocytes as a clinical marker in interferon therapy for chronic hepatitis B.
Furuta M; Akashi K; Nakamura Y; Matsumoto K; Yamaguchi H; Takamatsu S; Shimizu T
J Interferon Res; 1987 Feb; 7(1):111-9. PubMed ID: 3585079
[TBL] [Abstract][Full Text] [Related]
19. Phase I/IB study of polyadenylic-polyuridylic acid in patients with advanced malignancies: clinical and biologic effects.
Witt PL; Zahir S; Ritch PS; McAuliffe TM; Ewel CH; Borden EC
J Interferon Cytokine Res; 1996 Aug; 16(8):631-5. PubMed ID: 8877734
[TBL] [Abstract][Full Text] [Related]
20. Changes of serum neopterin, beta 2-microglobulin and interferon-gamma in patients with chronic hepatitis C treated with interferon-alpha 2b.
Fuchs D; Norkrans G; Wejstal R; Reibnegger G; Weiss G; Weiland O; Schvarcz R; Fryden A; Wachter H
Eur J Med; 1992; 1(4):196-200. PubMed ID: 1341444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
